[1] Sicras-Mainar A, Sicras-Navarro A, Palacios B, et al. Epidemiology and treatment of heart failure in Spain: the HF-PATHWAYS study. Rev Espanola Cardiol Engl Ed 2022; 75: 31−38. doi: 10.1016/j.recesp.2020.09.014 [2] van Riet EES, Hoes AW, Wagenaar KP, et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail 2016; 18: 242−252. doi: 10.1002/ejhf.483 [3] Anguita Sánchez M, Crespo Leiro MG, de Teresa Galván E, et al. Prevalence of heart failure in the Spanish general population aged over 45 years. The PRICE Study. Rev Esp Cardiol 2008; 61: 1041−1049. doi: 10.1157/13126044 [4] Franco J, Formiga F, Corbella X, et al. De novo acute heart failure: Clinical features and one-year mortality in the Spanish nationwide Registry of Acute Heart Failure. Med Clin (Barc) 2019; 152: 127−134. doi: 10.1016/j.medcli.2018.05.012 [5] Escobar C, Varela L, Palacios B, et al. Costs and healthcare utilisation of patients with heart failure in Spain. BMC Health Serv Res 2020; 20: 964. doi: 10.1186/s12913-020-05828-9 [6] McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993−1004. doi: 10.1056/NEJMoa1409077 [7] McDonald M, Virani S, Chan M, et al. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. Can J Cardiol 2021; 37: 531−546. doi: 10.1016/j.cjca.2021.01.017 [8] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599−3726. doi: 10.1093/eurheartj/ehab368 [9] Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2017; 70: 776−803. doi: 10.1016/j.jacc.2017.04.025 [10] Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med 2019; 380: 539−548. doi: 10.1056/NEJMoa1812851 [11]

Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019; 21: 1169−1186.

[12] Huerta-Preciado J, Franco J, Formiga F, et al. Differential characteristics of acute heart failure in very elderly patients: the prospective RICA study. Aging Clin Exp Res 2020; 32: 1789−1799. doi: 10.1007/s40520-019-01363-8 [13]

González-Franco Á, Cerqueiro González JM, Arévalo-Lorido JC, et al. Morbidity and mortality in elderly patients with heart failure managed with a comprehensive care model vs. usual care: The UMIPIC program. Rev Clin Esp 2022; 222: 123−130.

[14]

Arévalo Lorido JC, Carretero Gómez J, Gómez Huelgas R, et al. Comorbidity in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction. Cluster analysis of the RICA registry. Opportunities for improvement. Rev Clin Esp 2020; 220: 409−416.

[15] Guisado-Espartero ME, Salamanca-Bautista P, Aramburu-Bodas Ó, et al. Causes of death in hospitalized patients in internal medicine departments with heart failure according to ejection fraction. RICA registry. Med Clin (Barc) 2022; 158: 13−19. doi: 10.1016/j.medcli.2020.10.022 [16] Chilbert MR, Rogers KC, Ciriello DN, et al. Inpatient Initiation of Sacubitril/Valsartan. Ann Pharmacother 2021; 55: 480−495. doi: 10.1177/1060028020947446 [17] Peppin KL, Tellor KB, Armbruster AL, Schwarze MW. Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital. J Community Hosp Intern Med Perspect 2020; 10: 38−44. doi: 10.1080/20009666.2019.1708638 [18] Martyn T, Faulkenberg KD, Yaranov DM, et al. Initiation of Angiotensin receptor-neprilysin inhibitor in heart failure with low cardiac output. J Am Coll Cardiol 2019; 74: 2326−2327. doi: 10.1016/j.jacc.2019.09.006 [19] Akerman CC, Beavers JC. Risk factors for intolerance of inpatient sacubitril/valsartan initiation. J Pharm Pract 2021; 34: 454−458. doi: 10.1177/0897190019878948 [20] López-Azor JC, Vicent L, Valero-Masa MJ, et al. Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort. ESC Heart Fail 2019; 6: 1161−1166. doi: 10.1002/ehf2.12527 [21] Morrow DA, Velazquez EJ, DeVore AD, et al. Clinical outcomes in patients with acute decompensated heart failure randomly assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. Circulation 2019; 139: 2285−2288. doi: 10.1161/CIRCULATIONAHA.118.039331 [22] Jhund PS, Fu M, Bayram E, et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J 2015; 36: 2576−2584. doi: 10.1093/eurheartj/ehv330 [23] Mann DL, Givertz MM, Vader JM, et al. Effect of treatment with sacubitril/valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA Cardiol 2022; 7: 17−25. doi: 10.1001/jamacardio.2021.4567 [24] Ganesananthan S, Shah N, Shah P, et al. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study. Open Heart 2020; 7: e001305. doi: 10.1136/openhrt-2020-001305 [25] Giovinazzo S, Carmisciano L, Toma M, et al. Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis. ESC Heart Fail 2021; 8: 3547−3556. doi: 10.1002/ehf2.13547 [26] Mapelli M, Salvioni E, de Martino F, et al. Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction. J Cardiovasc Med Hagerstown Md 2020; 21: 882−888. doi: 10.2459/JCM.0000000000001018 [27] Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail 2019; 21: 998−1007. doi: 10.1002/ejhf.1498 [28] Molina A, Vicente M, Gasol M, et al. A drug utilization study of sacubitril/valsartan in Catalonia. Rev Espanola Cardiol Engl Ed 2019; 72: 593−595. doi: 10.1016/j.recesp.2018.06.013 [29] Damman K, Gori M, Claggett B, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail 2018; 6: 489−498. doi: 10.1016/j.jchf.2018.02.004 [30] Kristensen SL, Preiss D, Jhund PS, et al. Risk related to pre–diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction. Circ Heart Fail 2016; 9: e002560. doi: 10.1161/CIRCHEARTFAILURE.115.002560 [31] Balmforth C, Simpson J, Shen L, et al. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF. JACC Heart Fail 2019; 7: 457−465. doi: 10.1016/j.jchf.2019.02.015 [32]

McMurray JJV, Packer M. How should we sequence the treatments for heart failure and a reduced ejection fraction? Circulation 2021; 143: 875–877.

[33] Martínez-Milla J, García MC, Urquía MT, et al. Blockade of renin-angiotensin-aldosterone system in elderly patients with heart failure and chronic kidney disease: results of a single-center, observational cohort study. Drugs Aging 2019; 36: 1123−1131. doi: 10.1007/s40266-019-00709-1 [34] Franco Peláez JA, Cortés García M, Romero Daza AM, et al. Relationship between different doses of beta-blockers and prognosis in elderly patients with reduced ejection fraction. Int J Cardiol 2016; 220: 219−225. doi: 10.1016/j.ijcard.2016.06.178 [35]

Martínez-Milla J, García MC, Palfy JA, et al. Beta-blocker therapy in elderly patients with renal dysfunction and heart failure. J Geriatr Cardiol 2021; 18: 20−29.